Cromos Pharma, where the patients are

Novartis

GSK, Novartis, Eli Lilly swap assets to specialize, become more profitable

Wednesday, April 23, 2014 08:42 AM

In a major swap of assets, three of the world’s largest drug companies have announced a multi-part, $28.5 billion deal that enables Novartis to focus more on cancer, GlaxoSmithKline on vaccines and Eli Lilly on animal health.

More... »

CRF Health eCOA webinar series

Orphan drug market expected to grow through 2018

Monday, March 24, 2014 02:51 PM

The returns on investment from orphan drugs are expected to help pharma companies overcome the impact of revenue loss due to expiry of patents of blockbuster drugs, according to ReportsnReports.com.

More... »


Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »

Novartis expands clinical trial data transparency

Thursday, February 27, 2014 12:31 PM

Novartis has announced additional steps to extend its presence in clinical trial data transparency. Since 2005, and before requirements were in place, Novartis has been voluntarily disclosing summaries of Clinical Study Reports of its innovative medicines on its own web site (www.novctrd.com). In addition, the company is committed to enhancing Clinical Study Report summaries for all new pivotal studies to include easy to understand consumer language summaries and additional interpretation of data as of the end of 2014.

More... »

NIHR Clinical Research Network achieves 25 first global patients in one year

Wednesday, February 26, 2014 12:57 PM

The NIHRClinical Research Network has reached a milestone in study set-up achievements by recruiting 25 first global patients in commercial studies in the 2013-14 fiscal year.

More... »

Cinven to invest in Medpace

Monday, February 24, 2014 12:40 PM

European private equity firm Cinven has announced a majority investment in Medpace, for $915 million plus certain cash inflows relating to the period of ownership, acquired from CCMP Capital Advisors.

More... »

Novartis, Janssen, Eli Lilly, Aptiv Solutions co-found new consortium

Friday, February 21, 2014 11:05 AM

Aptiv Solutions, a global biopharmaceutical and medical device development services company, Novartis Pharma, Janssen Pharmaceuticals and Eli Lilly have joined in co-founding the ADDPLAN DF Consortium. The members of the consortium are collaboratively developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs. The ADDPLAN DF Consortium also will focus on enhancing the trial execution technologies required to handle the multiple adaptations integral to complex adaptive dose-finding trials. Aptiv Solutions will integrate and validate the methodologies that emerge from the ADDPLAN DF Consortium into its ADDPLAN DF software for the design, planning and analysis of dose finding trials, in addition to ensuring that these designs can be easily implemented through its proprietary execution platform.

More... »

Novartis acquires CoStim

Wednesday, February 19, 2014 01:20 PM

Novartis is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

More... »

goBalto expands internationally

Monday, January 13, 2014 11:48 AM

goBalto, a provider of clinical study start-up solutions, has opened its first international locations, in Singapore and the U.K.

More... »

Perrigo names board of directors

Friday, December 20, 2013 02:11 PM

Dublin, Ireland-based Perrigo has announced the appointment of its board of directors, effective until Perrigo’s annual general meeting scheduled for November 2014. The appointment of the Perrigo board follows the completion of Perrigo’s acquisition of Elan in a cash and stock transaction valued at approximately $8.6 billion. The transaction will create a global healthcare company with a growth profile.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs